Cartesian Therapeutics is at the forefront of developing mRNA cell therapies specifically targeting autoimmune diseases. Their lead candidate, Descartes-08, is an innovative mRNA CAR-T therapy designed to treat conditions such as generalized myasthenia gravis and systemic lupus erythematosus. Unlike traditional DNA-based CAR-T therapies, Descartes-08 does not require preconditioning chemotherapy and minimizes the risk of genomic integration, making it a potentially safer option for patients. The company is also advancing other candidates, including Descartes-15, which aims to provide predictable pharmacokinetics and further reduce the risks associated with conventional therapies.

The company’s proprietary RNA Armory® technology platform enhances the precision and optimization of engineered cells for various therapeutic applications. This platform supports the development of both autologous and allogeneic therapies, as well as in vivo transfection programs. Cartesian's commitment to in-house manufacturing at their state-of-the-art GMP facility allows for rapid process optimization and strict quality control, ensuring that their investigational therapies are not only potent but also cost-effective and safe for outpatient administration. Through these advancements, Cartesian Therapeutics aims to revolutionize the treatment landscape for autoimmune diseases.

United States

Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies to treat cancer and autoimmune diseases.

Cancer

Hematologic Diseases

Immune System Diseases

Lymphatic Diseases

Nervous System Diseases

Cartesian Therapeutics

Arthritis

Chronic refractory gout

SEL-212 is a novel combination product candidate designed to sustain control of serum uric acid (SUA) levels in patients with chronic refractory gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. SEL-212 consists of pegadricase, Selecta’s proprietary pegylated uricase, co-administered with ImmTOR, designed to mitigate the formation of anti-drug antibodies (ADAs). ADAs develop due to unwanted immune responses to biologic medicines, rendering these therapies less potent, which remains an issue across multiple therapeutic modalities and disease states including chronic refractory gout.

 SEL-212 (Pegadricase) 

Myasthenia gravis

Descartes-08

Systemic lupus erythematosus

Dermatomyositis

Descartes-25

Multiple myeloma

Descartes-15, the Company’s next-generation autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T).

Descartes-15

Descartes-19

Descartes-33

Genetic disorder

Methylmalonic acidemia

ImmTOR has significant potential to mitigate unwanted immune responses and induce AAV-specific tolerance to enable redosing of gene therapies. ImmTOR has the potential to administer multiple low doses to achieve therapeutic benefit without risk of overdosing, the ability to treat patients typically excluded from these treatments and is a novel approach to treating systemic diseases resulting from genetic disorders.
Gene therapy

Cartesian Therapeutics

Company Details